Axel Grothey

List of Publications by Year
in descending order

244	28,812	14615 66	5713 163
papers	citations	h-index	g-index

275	275	275	38142
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. European Journal of Cancer, 2023, 178, 162-170.	2.9	1
2	Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. European Journal of Cancer, 2023, 184, 137-150.	2.9	8
3	ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF^{V600E}-Mutant Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2023, 41, 2628-2637.	15.4	42
4	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	6.4	2
5	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	2.8	3
6	Impact of Circulating Tumor DNAâ€“Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	3.2	41
7	Landscape of KRAS^{G12C}, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precision Oncology, 2022, 6, e2100245.	3.2	40
8	Clinical Validation of a Machine-learningâ€“derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	7.2	34
9	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 1417-1427.	2.0	11
10	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110244.	3.2	9
11	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	3.4	3
12	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	15.4	104
13	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist, 2021, 26, 610-618.	4.1	5
14	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. Oncologist, 2021, 26, 651-659.	4.1	5
15	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1277.	7.0	70
16	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	10.8	264
17	Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clinical Cancer Research, 2021, 27, 4587-4598.	7.2	16
18	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. Current Colorectal Cancer Reports, 2021, 17, 55-68.	0.5	3

#	Article	IF	Citations
19	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Management and Research, 2021, Volume 13, 5523-5533.	2.0	6
20	Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer. JCO Oncology Practice, 2021, 17, 383-402.	2.8	14
21	Microsatellite Stable Colorectal Liver Metastasesâ€"Understanding the Mechanisms of Immune Resistance. JAMA Network Open, 2021, 4, e2119025.	6.0	5
22	Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting. Gynecologic Oncology, 2021, 162, S180.	1.4	1
23	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology and Hepatology, 2021, 6, 933-946.	8.2	88
24	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. Npj Precision Oncology, 2021, 5, 95.	5.5	10
25	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open, 2021, 6, 100328.	4.4	17
26	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist, 2020, 25, 404-413.	4.1	27
27	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	1.1	5
28	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	1.8	18
29	A new prognostic and predictive tool for shared decision making in stage III colon cancer. European Journal of Cancer, 2020, 138, 182-188.	2.9	33
30	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open, 2020, 5, e000942.	4.4	27
31	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Lancet Oncology, The, 2020, 21, 1620-1629.	10.8	170
32	Pembrolizumab in MSI-Hâ€"dMMR Advanced Colorectal Cancer â€" A New Standard of Care. New England Journal of Medicine, 2020, 383, 2283-2285.	30.1	26
33	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancerâ€"Fact or Fiction?. JAMA Oncology, 2020, 6, 823.	7.3	10
34	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	12.1	1,443
35	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. Cancers, 2020, 12, 1319.	3.8	11
36	Evolution of Cancer Care in Response to the COVID â€19 Pandemic. Oncologist, 2020, 25, e1426-e1427.	4.1	7

#	Article	IF	Citations
37	Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091091.	3.4	14
38	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist, 2020, 25, e936-e945.	4.1	533
39	Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open, 2020, 5, e000682.	4.4	72
40	Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews, 2020, 86, 101993.	8.0	68
41	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. Lancet Oncology, The, 2020, 21, 324-326.	10.8	8
42	Relationship between <scp>MLH1</scp>, <scp>PMS2</scp>, <scp>MSH2</scp> and <scp>MSH6</scp> geneâ€specific alterations and tumor mutational burden in 1057 microsatellite instabilityâ€high solid tumors. International Journal of Cancer, 2020, 147, 2948-2956.	5.4	114
43	Personalizing Treatment for Rectal Cancer. JAMA Network Open, 2020, 3, e2030508.	6.0	4
44	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncology, The, 2019, 20, 1070-1082.	10.8	182
45	Encorafenib, Binimetinib, and Cetuximab in BRAF V600Eâ€“Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	30.1	1,020
46	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	1.8	5
47	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	7.3	586
48	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	15.4	196
49	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. Supportive Care in Cancer, 2019, 27, 3869-3875.	2.3	10
50	Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Frontiers in Oncology, 2019, 9, 76.	2.9	37
51	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	4.1	96
52	Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. Journal of the American Society of Echocardiography, 2019, 32, 267-276.	2.7	22
53	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clinical Colorectal Cancer, 2019, 18, 52-57.	2.4	34
54	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	3.5	183

#	Article	IF	Citations
55	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 1083-1091.	4.1	43
56	MODULâ€"a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	2.6	32
57	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 359-369.	10.4	715
58	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. Oncologist, 2018, 23, 679-685.	4.1	18
59	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open, 2018, 3, e000347.	4.4	16
60	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	30.1	750
61	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). Journal of Geriatric Oncology, 2018, 9, 24-31.	1.1	11
62	Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 128-134.	4.1	35
63	Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clinical Colorectal Cancer, 2018, 17, e183-e187.	2.4	12
64	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 316-325.	7.2	18
65	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 2018, 119, 1451-1455.	6.6	19
66	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	2.9	13
67	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 961-969.	2.4	22
68	Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients. Drugs, 2018, 78, 737-745.	11.1	42
69	Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 611-615.	10.4	18
70	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	2.9	32
71	5-fluorouracil and cardiotoxicity: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878014.	3.4	273
72	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 852-871.	10.4	110

#	Article	IF	Citations
73	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 874-901.	10.4	729
74	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	1.5	0
75	European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Therapeutic Advances in Medical Oncology, 2017, 9, 4-12.	3.4	0
76	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs, 2017, 77, 1091-1103.	11.1	121
77	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 370-398.	10.4	726
78	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). American Journal of Hematology, 2017, 92, 1004-1010.	4.3	7
79	Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. JAMA Oncology, 2017, 3, 885.	7.3	5
80	Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncology, The, 2017, 18, 1427-1428.	10.8	2
81	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 124-128.	2.4	38
82	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	3.4	38
83	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Management and Research, 2017, Volume 9, 149-158.	2.0	15
84	^{Non-V600}BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 2624-2630.	15.4	281
85	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en CancÃ©rologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	15.4	43
86	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.4	87
87	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Investigational New Drugs, 2016, 34, 96-103.	2.7	2
88	Colorectal cancer: how to teach an old drug new tricks. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 384-385.	18.1	1
89	Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncology, The, 2016, 17, 663-670.	10.8	92
90	Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer, 2016, 16, 467.	2.6	57

#	Article	IF	Citations
91	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist, 2016, 21, 1306-1314.	4.1	37
92	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer, 2016, 24, 5059-5068.	2.3	71
93	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	4.1	37
94	Adverse event development in clinical oncology trials â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e264-e265.	10.8	1
95	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	10.8	479
96	Chemotherapy Maintenance. Cancer Journal (Sudbury, Mass), 2016, 22, 199-204.	2.0	31
97	Adjuvant Therapy for Colon Cancer. JAMA Oncology, 2016, 2, 1133.	7.3	8
98	Regorafenib in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 137-145.	1.9	11
99	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	15.4	33
100	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Supportive Care in Cancer, 2016, 24, 1071-1078.	2.3	50
101	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	10.4	185
102	Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 682-685.	10.4	2
103	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1097-1101.	10.4	11
104	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	2.1	8
105	Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-7.	0.4	5
106	Rationale for metronomic chemotherapy in phase III trials. Nature Reviews Clinical Oncology, 2015, 12, 313-314.	27.6	25
107	The role of regorafenib in metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 596-597.	10.8	6
108	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute, 2015, 107, djv239.	6.4	21

#	Article	IF	Citations
109	Is obesity an advantage in patients with colorectal cancer?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1339-1342.	3.0	22
110	The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. Journal of the National Cancer Institute, 2015, 107, djv216.	6.4	65
111	Progress in defining first-line and maintenance therapies. Nature Reviews Clinical Oncology, 2015, 12, 73-74.	27.6	39
112	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investigational New Drugs, 2015, 33, 740-750.	2.7	95
113	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.8	294
114	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2015, 41, 653-659.	8.0	52
115	When less is more: maintenance therapy in colorectal cancer. Lancet, The, 2015, 385, 1808-1810.	12.1	13
116	Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. Expert Review of Gastroenterology and Hepatology, 2015, 9, 273-276.	3.0	11
117	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncology, The, 2015, 16, 499-508.	10.8	779
118	Distinctive Tumor Biology of MSI-High Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 281-287.	0.5	1
119	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). Journal of Clinical Oncology, 2015, 33, 3416-3422.	15.4	231
120	New Adjuvant Trial Designs in Colon Cancer. Current Colorectal Cancer Reports, 2015, 11, 326-334.	0.5	2
121	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	15.4	88
122	Metastatic extramammary Paget's disease responding to weekly paclitaxel. BMJ Case Reports, 2015, 2015, bcr2014208653.	0.5	4
123	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiology & Pain Management, 2015, 2, .	0.1	10
124	The search for treatments to reduce chemotherapy-induced peripheral neuropathy. Journal of Clinical Investigation, 2014, 124, 72-74.	8.2	16
125	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. Oncologist, 2014, 19, 669-680.	4.1	62
126	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.4	67

#	Article	IF	Citations
127	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.	2.4	41
128	Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 726-734.	1.9	45
129	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	6.4	144
130	The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt442-djt442.	6.4	1
131	Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology, 2014, 32, 997-1005.	15.4	191
132	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. Journal of Clinical Oncology, 2014, 32, 841-850.	15.4	42
133	Drug rechallenge and treatment beyond progressionâ€"implications for drug resistance. Nature Reviews Clinical Oncology, 2013, 10, 571-587.	27.6	228
134	A Home-Based Exercise Program to Improve Function, Fatigue, and Sleep Quality in Patients With Stage IV Lung and Colorectal Cancer: A Randomized Controlled Trial. Journal of Pain and Symptom Management, 2013, 45, 811-821.	1.2	230
135	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	12.1	2,360
136	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Âmonths) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports, 2013, 9, 261-269.	0.5	95
137	Regorafenib for metastatic colorectal cancer â€" Authors' reply. Lancet, The, 2013, 381, 1538-1539.	12.1	9
138	VEGF inhibition beyond tumour progression. Lancet Oncology, The, 2013, 14, 2-3.	10.8	9
139	Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. Hpb, 2013, 15, 116-118.	0.3	4
140	Phase III Randomized, Placebo(Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1. Annals of Oncology, 2013, 24, iv24.	1.3	4
141	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	15.4	66
142	Adolescent and Young Adult Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1219-1225.	10.4	50
143	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1383.	7.0	419
144	Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications. Oncologist, 2012, 17, 725-731.	4.1	32

#	Article	IF	Citations
145	Reply to M. MandalÃ et al. Journal of Clinical Oncology, 2012, 30, 1895-1895.	15.4	0
146	Reply to S.A. Kesikli et al. Journal of Clinical Oncology, 2012, 30, 2288-2289.	15.4	1
147	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 301-319.	3.4	26
148	Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas. Clinical Cancer Research, 2012, 18, 546-554.	7.2	132
149	Establishing a Standard of Care for Small Bowel Adenocarcinomas: Challenges and Lessons Learned. Oncologist, 2012, 17, 1133-1134.	4.1	0
150	A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES. Retina, 2012, 32, 1959-1966.	1.9	71
151	Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOXâ€“Bevacizumab or FOLFIRIâ€“Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. Oncologist, 2012, 17, 1486-1495.	4.1	91
152	Treatment options for advanced pancreatic cancer: a review. Expert Review of Anticancer Therapy, 2012, 12, 1327-1336.	2.6	36
153	S-1 in colorectal cancer: a new standard of care?. Lancet Oncology, The, 2012, 13, 1068-1070.	10.8	0
154	O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC). Annals of Oncology, 2012, 23, iv15-iv16.	1.3	1
155	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Cancer, 2012, 118, 1083-1090.	4.1	37
156	Optimal Treatment Strategies for Localized and Advanced Microsatellite Instabilityâ€“High Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 36-41.	0.5	0
157	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	3.4	126
158	Should Oncologists Routinely Discuss Fertility Preservation With Cancer Patients of Childbearing Age?. Mayo Clinic Proceedings, 2011, 86, 6-7.	2.8	6
159	Recent developments in therapy for gastrointestinal cancers. Community Oncology, 2011, 8, 4-8.	0.1	0
160	Adjuvant Hepatic Arterial Infusional Chemotherapy. Annals of Surgery, 2011, 254, 857-859.	4.5	0
161	Reduced Chemotherapy Duration: A Good Idea?. Current Colorectal Cancer Reports, 2011, 7, 241-245.	0.5	0
162	Curable Metastatic Colorectal Cancer. Current Oncology Reports, 2011, 13, 168-176.	4.1	43

#	Article	IF	Citations
163	Prognostic webâ€based models for stage II and III colon cancer. Cancer, 2011, 117, 4155-4165.	4.1	26
164	Reply to A. Chan et al. Journal of Clinical Oncology, 2011, 29, e490-e491.	15.4	0
165	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. Oncologist, 2011, 16, 859-867.	4.1	16
166	KRAS and Colorectal Cancer: Ethical and Pragmatic Issues in Effecting Real-Time Change in Oncology Clinical Trials and Practice. Oncologist, 2011, 16, 1061-1068.	4.1	16
167	Does Stage II Colorectal Cancer Need to Be Redefined?. Clinical Cancer Research, 2011, 17, 3053-3055.	7.2	7
168	Antiangiogenesis agents in colorectal cancer. Current Opinion in Oncology, 2010, 22, 374-380.	2.5	28
169	The Role of Chemotherapy in Managing Patients With Resectable Liver Metastases. Cancer Journal (Sudbury, Mass), 2010, 16, 125-131.	2.0	7
170	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Annals of Surgical Oncology, 2010, 17, 947-949.	2.0	5
171	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology, 2010, 28, 3227-3233.	15.4	201
172	Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. Current Colorectal Cancer Reports, 2010, 6, 126-132.	0.5	0
173	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. Seminars in Oncology, 2010, 37, 39-46.	2.3	21
174	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1936-1941.	15.4	97
175	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e652-e653.	15.4	3
176	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	15.4	71
177	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 2010, 28, 3219-3226.	15.4	1,398
178	Biomarkers and surrogate end pointsâ€"the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	27.6	287
179	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	15.4	79
180	Review: Medical treatment of advanced colorectal cancer in 2009. Therapeutic Advances in Medical Oncology, 2009, 1, 55-68.	3.4	7

#	Article	IF	Citations
181	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	15.4	163
182	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 2009, 27, 3677-3683.	15.4	1,193
183	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2009, 27, 872-877.	15.4	556
184	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7492-7501.	7.2	45
185	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. Oncologist, 2009, 14, 862-870.	4.1	296
186	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	15.4	0
187	Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. Current Colorectal Cancer Reports, 2009, 5, 65-66.	0.5	0
188	A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer. Nature Clinical Practice Oncology, 2009, 6, 10-11.	2.3	6
189	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology, 2009, 6, 507-518.	27.6	337
190	Should bevacizumab be continued beyond progression in colorectal cancer?. Current Colorectal Cancer Reports, 2008, 4, 139-143.	0.5	0
191	North Central Cancer Treatment Groupâ€"Achievements and Perspectives. Seminars in Oncology, 2008, 35, 530-544.	2.3	6
192	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 60-64.	2.4	28
193	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology, 2008, 26, 5326-5334.	15.4	657
194	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	15.4	172
195	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. Molecular Therapy, 2008, 16, 979-984.	8.1	46
196	Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Statistical Methods in Medical Research, 2008, 17, 529-535.	1.6	8
197	Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. Cancer Journal (Sudbury, Mass), 2008, 14, 170-177.	2.0	65
198	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics: Targets and Therapy, 2008, 2, 223.	3.5	33

#	Article	IF	Citations
199	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	4.1	219
200	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. Journal of Clinical Oncology, 2007, 25, 3191-3193.	15.4	2
201	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology, 2007, 25, 4217-4223.	15.4	259
202	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer, 2007, 110, 670-677.	4.1	29
203	Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data. Journal of Clinical Oncology, 2006, 24, 2903-2909.	15.4	1,066
204	Randomized Phase III Trial Results of Panitumumab, a Fully Human Antiâ€"Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 29-31.	2.4	141
205	Do All Patients with Metastatic Colorectal Cancer Need Chemotherapy Until Disease Progression?. Clinical Colorectal Cancer, 2006, 6, 196-201.	2.4	7
206	Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial. Clinical Colorectal Cancer, 2006, 6, 261-264.	2.4	26
207	Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement. Annals of Surgical Oncology, 2006, 13, 1261-1268.	2.0	341
208	Future Directions in Vascular Endothelial Growth Factorâ€"Targeted Therapy for Metastatic Colorectal Cancer. Seminars in Oncology, 2006, 33, S41-S49.	2.3	13
209	Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy?. Nature Clinical Practice Oncology, 2006, 3, 22-23.	2.3	1
210	First- and second-line therapy of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 921-930.	2.6	17
211	Does Lifestyle Cause Colorectal Cancer?. , 2006, , 1-13.		1
212	The Role of the Colorectal Nurse Specialist in the Management of Colorectal Cancer. , 2006, , 153-166.		1
213	Minimally Invasive Surgery â€" Where are We? is there a Role for TEM?. , 2006, , 73-88.		1
214	The Role of the Multidisciplinary Team in the Management of Colorectal Cancer. , 2006, , 167-177.		1
215	Followâ€Up after Colorectal Cancer Resection: Is it Worth While?. , 2006, , 178-194.		0
216	Surgery for Metastatic Disease in Colorectal Cancer. , 2006, , 213-231.		0

#	Article	IF	Citations
217	Palliative Care of the Colorectal Cancer Patient. , 2006, , 232-250.		0
218	Future Directions in the Oncological Treatment of Colorectal Cancer. , 2006, , 251-270.		0
219	Screening for Colorectal Cancer â€" Who, When, and How?. , 2006, , 14-30.		0
220	What can the Pathologist Tell the Multidisciplinary Team about Rectal Cancer Resection?. , 2006, , 31-45.		0
221	MRIâ€Directed Rectal Cancer Surgery. , 2006, , 46-59.		0
222	Minimally Invasive Surgery â€" Where are We? Laparoscopic Surgery for Cancer of the Colon and Rectum. , 2006, , 60-72.		0
223	What is the Best Strategy for the Management of Hereditary Colorectal Cancer?. , 2006, , 89-111.		0
224	Adjuvant Radiotherapy and Chemoradiotherapy in the Treatment of Rectal Cancer. , 2006, , 112-132.		0
225	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. European Journal of Haematology, 2005, 74, 263-266.	2.2	56
226	Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Supportive Care in Cancer, 2005, 13, 26-31.	2.3	19
227	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2005, 23, 8664-8670.	15.4	617
228	Clinical Trial Designs for Prospective Validation of Biomarkers. Molecular Diagnosis and Therapy, 2005, 5, 317-325.	3.5	45
229	N0147: A Randomized Phase III Trial of Oxaliplatin plus 5-Fluorouracil/Leucovorin with or Without Cetuximab After Curative Resection of Stage III Colon Cancer. Clinical Colorectal Cancer, 2005, 5, 211-213.	2.4	29
230	A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2159-2170.	1.9	98
231	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	15.4	1,011
232	Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 627-637.	2.6	4
233	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colorectal Cancer, 2004, 4, 46-50.	2.4	28
234	Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S37-S42.	2.4	14

#	Article	IF	Citations
235	Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland. Medizinische Klinik, 2002, 97, 270-277.	0.3	29
236	New chemotherapy approaches in colorectal cancer. Current Opinion in Oncology, 2001, 13, 275-286.	2.5	58
237	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. Journal of Cancer Research and Clinical Oncology, 2001, 127, 96-100.	2.6	12
238	Cyclooxygenase-2: a novel target for cancer chemotherapy?. Journal of Cancer Research and Clinical Oncology, 2001, 127, 411-417.	2.6	382
239	Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs, 2000, 11, 225-236.	1.4	102
240	C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene, 2000, 19, 4864-4875.	5.9	107
241	Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clinical and Experimental Metastasis, 1999, 17, 171-176.	3.5	14
242	Diagnostisches und therapeutisches Management der oberen EinfluÃŸstauung. Medizinische Klinik, 1999, 94, 681-684.	0.3	15
243	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anti-Cancer Drugs, 1999, 10, 545-550.	1.4	3
244	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anti-Cancer Drugs, 1998, 9, 405-409.	1.4	11